Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer

Clinical Cancer Research

Volumn 10, Issue 11, 2004, Pages 3927-3933

  Kelloff, Gary J ^a   Coffey, Donald S ^b   Chabner, Bruce A ^c   Dicker, Adam P ^d   Guyton, Kathryn Z ^e   Nisen, Perry D ^f   Soule, Howard R ^g   D'Amico, Anthony V ^h  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^e CCS Associates   (United States)

^f ABBOTT LABORATORIES   (United States)

^g CaP CURE   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; FLUTAMIDE; GOSERELIN; LEUPRORELIN; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; NILUTAMIDE; PANITUMUMAB; PROSTATE SPECIFIC ANTIGEN; REBIMASTAT; TRIPTORELIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DRUG EFFICACY; EARLY CANCER; HUMAN; MALE; MORBIDITY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT INDICATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COHORT STUDIES; DRUG DESIGN; HUMANS; KINETICS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 2542590276     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0788     Document Type: Review

References (45)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA-Cancer J Clin 2004;54:8-29.
2. Penson DF, Litwin MS. The physical burden of prostate cancer. Urol Clin N Am 2003;30:305-13.
3. O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002;8:314-46.
4. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548-52.
5. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948-54.
6. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-51.
7. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001;58:843-8.
8. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst (Bethesda) 1998;90:766-71.
9. de la Taille A, Flam TA, Thiounn N, et al. Predictive factors of radiation therapy for patients with prostate specific antigen recurrence after radical prostatectomy. BJU Int 2002;90:887-92.
10. Benaim EA, Pace CM, Lam PM, Roehrborn CG. Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer. Urology 2002;59:73-8.
11. Kwak C, Jeong SJ, Park MS, Lee E, Lee SE. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 2002;168:995-1000.
12. Hachiya T, Minei S, Kobayashi K, Ishida H, Okada K. Prediction of organ-confined disease by prostate-specific antigen nadir after neoadjuvant therapy. Int J Urol 2000:7:393-401; discussion 402-3.
13. Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152:1821-5.
14. Patel A, Dorey F, Franklin J, deKernion JB. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997;158:1441-5.
15. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
16. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002;20:4567-73.
17. D'Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst (Bethesda) 2003;95:1376-83.
18. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003;21:383-91.
19. Kucera E, Kainz C, Tempfer C, et al. Prostate specific antigen (PSA) in breast and ovarian cancer. Anticancer Res 1997;17:4735-7.
20. Svetec D, Thompson IM. PSA screening: current controversy. Ann Oncol 1998;9:1283-8.
21. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;270:860-4.
22. Morgan TO, Jacobsen SJ, McCarthy WF, et al. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 1996;335:304-10.
23. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.
24. Kattan MW, Shariat SF, Andrews B, et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 2003;21:3573-9.
25. See W, Iversen P, Wirth M, et al. Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. Eur Urol 2003;44:512-8.
26. Peschel RE, Colberg JW. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol 2003;4:233-41.
27. FDA approves new drug for advanced prostate cancer 11-25-2003. http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01268.html. FDA/CDER. Accessed February 17, 2004.
28. Perez CA, Michalski JM, Lockett MA. Chemical disease-free survival in localized carcinoma of prostate treated with external beam irradiation: comparison of American Society of Therapeutic Radiology and Oncology consensus of 1 ng/ml as endpoint. Int J Radiat Oncol Biol Phys 2001;49:1287-96.
29. Hanlon AL, Diratzouian H, Hanks GE. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 2002;53:297-303.
30. Yashi M, Nukui A, Kurokawa S, et al. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer. Prostate 2003;56:305-12.
31. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-20.
32. Fang J, Metter EJ, Landis P, Carter HB. PSA velocity for assessing prostate cancer risk in men with psa levels between 2.0 and 4.0 ng/ml. Urology 2002;59:889-93;discussion 893-4.
33. Carter HB, Pearson JD. Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Urol Clin N Am 1997;24:333-8.
34. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
35. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-her2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
36. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
37. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
38. Druker BJ. Imatinib alone and in combination for chronic myeloid leukemia. Semin Hematol 2003;40:50-8.
39. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001;98:2039-42.
40. Figg WD, Kruger EA, Price DK, Kim S, Dahut WD. Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Investig New Drugs 2002;20:183-94.
41. Bander NH, Nanus DM, Milowsky MI, et al. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003;30:667-76.
42. Lassiter LK, Carducci MA. Endothelin receptor antagonists in the treatment of prostate cancer. Semin Oncol 2003;30:678-88.
43. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (Bethesda) 2000;92:205-16.
44. Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001;76:576-81.
45. Schmid HP, Maibach R, Bernhard J, et al. A Phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland. Cancer (Phila) 1997;79:1703-9.